The National Cancer Institute: Cancer drug discovery and development program

Seminars in Oncology

Volumn 19, Issue 6, 1992, Pages 622-638

  Grever, Michael R ^a   Schepartz, Saul A ^a   Chabner, Bruce A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; DAUNORUBICIN; FOSTRIECIN; HALICHONDRIN B; IRINOTECAN; PACLITAXEL; PENCLOMEDINE; PICRIC ACID; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RESEARCH; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DETERMINATION; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

ANIMAL; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG EVALUATION; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; FORECASTING; HUMAN; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; UNITED STATES;

EID: 0026676380     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. The chemotherapy program of the national cancer institute: History, analysis, and plans
2. The preclinical new drug research program of the National Cancer Institute
3. Drug development for cancer: Implications for chemical modifiers
4. New colorimetric cytotoxicity assay for anticancer drug screening
5. New soluble formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS-antiviral activity
6. Discovery and development of antineoplastic agents from natural sources
7. Computer-aided selection of compounds for antitumor screening: Validation of a statistical-heuristic method
8. In defense of cell-line screening
9. Anticancer drug discovery
10. Status of the NCI Preclinical Antitumor Drug Discovery Screen
11. Screening at the National Cancer Institute: Basic concepts
12. Neural computing in cancer drug development
13. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE Algorithm
14. Halichondrin B and Homohaichondrin B, marine natural products binding in the vinca domain of tubulin: Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data
15. Clinical pharmacokinetics of 2′-deoxycoformycin
16. Pharmacokinetics of 2-F-ara-A (9-B-D-Arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine monophosphate
17. Potential roles for preclinical pharmacology in phase I clinical trials
18. Pharmacologically guided phase I clinical trials based upon preclinical drug development
19. The formulation of anticancer drugs
20. Metabolism and chemotherapeutic activity of 9-B-D-Arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase
21. Taxol: Twenty years later, the story unfolds
22. Relation of preclinical toxicology to findings in early clinical trials
23. The current toxicology protocol of the National Cancer Institute
24. The efficacy of animal studies in predicting clinical toxicity of cancer chemotherapeutic drugs
25. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development
26. Taxol
27. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer
28. Phase I and pharmacologic study of topotecan (SK&F 104864): A novel topoisomerase inhibitor
29. Phase I and clinical pharmacologic study of intravenous topotecan
30. An early phase II study of CPT-11: A new derivative of camptothecin, for the treatment of leukemia and lymphoma
31. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts
32. A phase II study of a new camptothecin derivative, CPT-11 in previously untreated non-small cell lung cancer
33. Clinical study of CPT-11, camptothecin derivative on gynecologic malignancy
34. Phase II study of CPT-11, new camptothecin derivative in the patients with metastatic colorectal cancer
35. Preclinical antitumor activity of an a-picoline derivative, penclomidine (NSC 338720), on human and murine tumors
36. Temozolomide (CCRG 81045; M&B 39831; NSC 362856): A new oral cytotoxic agent with activity against melanoma, mycosis fungoides, and high-grade glioma
37. In vitro activity of the novel antitumor antibiotic fostriecin (CI-920) in a human tumor cloning assay
38. Inhibition of type II topoisomerase by fostriecin
39. Potent anti-angiogenic action of AGM-1470: Comparison to fumagillin parent
40. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
41. Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition
42. Design, activity, and 2.8 a crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease
43. Overlapping cDNA clones define the complete coding region for the p210 (c-abl) gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome
44. Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene
45. Tyrosine kinase activity and transformation potency of BCR-ABL oncogene products
46. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner
47. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL
48. Induction of chronic myelogenous leukemia in mice by the P210 (BCR-ABL) gene of the Philadelphia chromosome
49. Acute leukemia in BCR-ABL transgenic mice
50. O6-Methylguanine DNA methyltransferase (MGMT) mRNA levels and in vitro sensitivity of human tumor cell lines to alkylating agents
51. Screening methods in antineoplastic drug discovery
52. Mechanism-based discovery of anticancer agents